First
in Global Disease and Addiction Testing and Management
CCR Deployment
Funding Business Case
Authors:
Steve
Rattley, Connor McHale, Cam Babula (Owners)
Recipient:
Prof A Lynch
PhD, Mercer Country Community College
Release Date:
4th April 2022
Review Date:
4th May 2022
Version:
0.1
Document Control: Steve Rattley, CEO, CCR Tower, Budd Lake, New
Jersey. 07828
Contents
1. Cover Page 1
2. Table of Contents 2
3. Executive Summary 4
4. Business Description 5
A.
Mission Statement 5
B. Type of Business 5
C. Purpose of Business 5
D. Name of Business 6
E. Location of Business 6
F. Service Description and Uniqueness 7
G.
Disease Testing 7
H.
Addiction Management 8
H. Pricing Strategy 8
5. Market and Industry
Analysis 10
A.
Customer Profile and Demographics 10
B.
Market Segment and Targets 11
C.
Market Trend 11
D.
Competitors 12
6. Sales and Marketing 13
A.
Strategy 13
B.
Method of sales 13
C.
Online Advertising 14
D.
Testimonials/Newspaper Advertising 14
E. In Person Representation and Demonstration
(B2B) 14
F. B2B Bundles 15
G.
Estimated Sales Potential USA 15
H.
Promotion Plan for Market Penetration 16
I. 4 P’s Summary 16
J. Distribution Channels 17
K.
Ongoing Growth Ambition 17
L.
Slogan 18
M.
Character/Spokesman 18
7. Management and
Ownership 19
A.
Legal and Regularity Responsibilities 19
8. Financials 22
A. Risks 22
B.
Testing Margins 23
C.
Balance Sheet 24
D. Income Statement 25
E. Sales – April 2022 25
F. Kit Costs – April 2022 26
G.
Capital Requirement 26
Executive
Summary
Introduction
CCR will operate as a specialist company that improves the wellbeing of
the nation by providing a simple and convenient disease diagnostic service in
the customers’ home. Our strategy for a US start-up is low risk and utilizes
the best practices known to date and builds on the Covid initial, knee jerk
federal sponsored expertise and develops it into a long-term, for-profit
service that can be offered to businesses, colleges, government and
individuals. Utilizing accurate testing, reliable supply and logistics
and efficient management processes will give CCR a commercial advantage in a
growing market segment. As well as the familiar “test by post” Covid Testing, the
unique selling point of CCR comes in 3 parts:
1.
The CCR Premium Covid Testing
Service: In-home and virtually instant results.
Service.
2.
Addiction Management programme. A co-ordinated testing and counselling
service.
3.
Testing for other diseases including HIV,
Hep B, Flu, MMR, Yellow Fever.
We consider that the economic shock of the Covid-19 lockdowns, resulting
depression and other impacts on the USA has created an opportunity for this
type of service - especially in the corporate world - that will become as
commonplace a benefit as private health care. CCR seeks to be a pioneer
and exploit the potential for rapid growth in a new and expanding market.
CCR will be agile and provide a testing service designed for the client and
delivered in the privacy of their own living/work spaces and at a competitive
price.
This proposal works with the present economic and cultural world and
will grow as the lessons of the present pandemic crystalise. CCR does not
seek to exploit the pandemic. Instead, it seeks to act against it and be
a positive element in an emerging market sector delivering accurate health
information on demand, in privacy and in time to be truly effective in
maintaining national and personal output.
Business Description
Mission
Statement
Fast,
convenient, accurate and discrete disease and addiction management available to
all. CCR is committed to preserving
health and prosperity across the world enabling the world economy to grow,
saving lives and protecting families.
Type
of Business
A
closely held corporation, CCR seeks to be the global leader in disease and
addiction detection and management. CCR
began as the brainchild of Steve Rattley, Cameron Babula and Connor
McHale. The need for fast and convenient
disease management was identified as an ongoing product necessary for
individuals and business clients as a way of mitigating the effects of the
global Covid pandemic and the inevitable normalising of this into an endemic
disease. Covid is not going away and the
need to manage it will not either.
Additional
diseases and then addiction was also then considered and joined the product mix
for CCR. These exploit our testing
capability and diversify CCR. The
addiction management service further enhances our diversity by again using our
testing capability and with the inclusion of a counselling package, further
diversifies our product offering. CCR
will be unique in offering individual clients and business a “one-stop-shop”
regarding these major health concerns and will ensure high work attendance and
early disease outbreaks are identified early.
Businesses will be able to de-risk labor shortages and individuals will
keep themselves safer, by way of early diagnosis, and protect their families
and friends.
Purpose
of the Business
CCR
is designed to take market share from government and other diagnostic and
addiction management businesses and become a world leader due to the blend and
convenience of its services. CCR will
set new standards in effective disease control working directly with its
clients at a location of the client’s choice and according to the client’s
timeline. CCR Vision is to transform the
disease management market by introducing services that improve our client’s
health, their prosperity, and the profits of business in a Covid world.
This
industry is new and CCR seeks to play in a vast market. CCR intends to be at the forefront of this
new market and shape it with its innovation and lean processes throughout. It seeks to offer disease testing and
management for more than just Covid.
HIV, SARS, Lyme’s and STD are just a selection of the disease management
services CCR will offer.
Name
of Business
“CCR Disease and Addiction Management Corp”
Location
The
CCR strategic plan is to launch in the USA, then expand across the North
American continent before offering its market transforming services to the
world. CCR offer a scalable, discrete,
fast and accurate disease testing and addiction management service. CCR is a provider of disease and addiction
testing and management services. Due to its scale the business is already
incorporated (in the USA) and will seek further funding from its growing
shareholder base as well as from fresh investors that are currently drawn to
this new type of enterprise. We plan to
offer new stock options as the business grows with a good dividend year on
year.
Presently,
the company founders Messrs, Babula, McHale and Rattley own 75% of the parent
company, Medical Services Inc, trading as CCR
. Head office, logistical hub and initial
testing/R&D laboratories are working up in Philadelphia now. Presently CCR is trading and offering its
services to the eastern seaboard of the US.
Sales are currently running at some $10m per month and growing. Philadelphia was carefully chosen and offers
the following advantages:
a. 7th
Largest Life Sciences Centre in the USA (See Annex A)
b. 20%
of the Philadelphia workforce work in the Biotech field (See Annex B)
c. Excellent
transport links to the major cities of the eastern seaboard.
Service Description and Uniqueness
Disease Testing. CCR Business capture will utilise an online
portal to take orders 24/7 and guide/inform the customer through the entire
testing service. 24hr testing labs, mobile testing labs, digital
ordering/payment/progress, enable testing completion within 12hrs (Premium
Service) from initial contact when using the CCR Premium Testing Service (97%
Confidence on the eastern seaboard – Washington to Boston). A flow chart of the service is given below:
 |
CCR
will offer the following Tests: HIV, HPA, Gonorrhoea, Syphilis, Chlamydia, Genital Herpes, Hep
B, Flu, MMR, Yellow Fever, Lyme’s Disease, Alcohol, Opiates, Cocaine, Cannabis,
PCP, Crystal Meth, MDA. (Doctors Certificate required where appropriate).
Our mobile testing labs will provide results to the client where the
Premium Testing service is requested.
This is a mobile laboratory that takes the sample from the customer and
returns the sample to the mobile lab with the results being passed to the
customer upon completion. These mobile
laboratories range from small vans for individual client to articulated lorries
for larger, corporate size requirements.
Addiction
Management Service. Addiction
is a disease like any other and CCR seeks to offer services to manage, control
and defeat addiction to alcohol and drugs.
CCR offers a fast diagnosis using our testing labs together with
counselling services. The testing looks
for ongoing presence of alcohol and drugs and the counselling deals with the
associated addiction drivers and creates the correct mental state for
recovery. This is new to the marketplace
and our services will come to the home or workplace to enable suffers the best chance
of success on their journey to an addiction free existence benefitting both the
individual’s health and the economy.
CCR is unique in it offers a combination of conventional and
ground-breaking services that provide an individual and business clients a
complete disease management programme from one supplier at a market altering
cost.
Pricing
Strategy
CCR
will trade on price and convenience. A
typical Covid 19 Antibody test costs upwards of $99 (CVS, 04/30/22). CCR will slash this cost to less than $10 and
offer the service at home. CCR research
believes that by sourcing its test from abroad this is viable due to inhouse
concentration of logistics and testing with online ordering only. Once CCR penetrate the market our lower cost
will dramatically drive sales. Table 1
gives a projection of a US wider market potential. Table 2 and 3 gives the initial costs/price
of the CCR Covid testing service.
Table 1: Costs Headlines
|
Fixed Costs (300m Tests Capacity) |
US Dollars |
|
Antibody Testing |
$150m |
|
Gnome
Testing |
$1500m |
|
Other
Testing |
$100m |
|
Fixed
Costs (ex Labor) |
$300m |
|
Labor |
$400m |
|
Total Costs |
$2495m |
|
|
|
|
Revenue @30% mark up over costs (FY1) |
$748.5m |
Table 2: Pricing Headlines – Standard Service
|
|
Total
Cost ($) |
Retail Per Test ($) |
|
C19
- Antibody |
0.73 |
0.95 |
|
C19
- Gnome |
7.1 |
9.14 |
Table 3: Pricing
Headlines - Premium Service
|
|
Total
Cost ($) |
Retail Per Test ($) |
|
C19
- Antibody |
0.73 |
1.10 |
|
C19
- Gnome |
7.1 |
10.65 |
We
intend to sell on price. A simple mark
up of 15%, based on the above volumes would be our break-even point. profits in
excess of $225m (best case assuming 300m tests are sold).
Market And Industry Analysis
Customer
Profile/Demography
Our
customers are all those who need disease identification and or counselling to
recover. Given the nature of Covid 19 we
expect the over 18’s to be the most likely to require our services. The need is omnipresent across humanity. Young and old, poor or wealthy employed and
unemployed; all will require these services.
This makes the CCR potential for growth unlimited in that our only
restriction on customers is the ability to pay.
Given propensity for variants of Covid it seems likely that the need for
Covid testing will remain and to a lesser extent – due to reduced prevalence –
the need for testing for other diseases will also remain. CCR will assist all customers with their
medical insurance claims and verbal agreement with the US medical insurers has
been sought and is positive and constructive.
They want to work with us to develop a seamless payment process.
To
start, our customer base will be limited to the eastern seaboard of the USA
before CCR expands its operations across the continent. Then CCR intends to expand globally. The global market is of especial interest as
the US has a well-developed heath care system.
This is not present in other countries and offers CCR untapped markets.
Business
customers attract special attention.
Large organisations looking to identify and ringfence Covid outbreaks
before it impacts production are a priority for CCR. Due to economies of scale regarding
deployment of the Rapid Response Teams means higher margins. Our marketing will reflect this making B2B awareness
of CCR a major priority. The nature of
Covid, although tragic, does increase the probability of take of CCR services
in larger organisations. Likewise, the
addiction service will be proposed to corporate and government organisations to
augment their extant benefits packages.
In
terms of numbers, the customer base for CCR can be summarised as follows
(Figures from US Census Bureau):
Over
18’s in US = 77.9% of the population = 258.3m
Persons
The
growth in population (therefore demand) in the next 10 years is estimated at
10.1% or 73.1m extra persons.
Total
world population wef 2021 = 7.9bn Persons
Market Segment and
Targets
Initially,
CCR has launched on the eastern seaboard of the USA. Expanding across the US gives CCR a market of
300m potential customers. CCR’s
strategic plan states this to occur in its 2nd trading year. Start-up +year 3-4 will see CCR expand into
the global market whether by direct ownership, partnering or franchise. The potential market for these services is
therefore 7bn people. According to
Fortune Business Insights the Covid Diagnostic Market in the USA is currently
worth (Fortune Business. Retrieved
04/30/22. Online) $12.5Bn.
Starting
in the US before expanding across the globe CCR will use existing and already
secured laboratory capacity. In
addition, CCR will develop its revolutionary mobile testing capability to
provide near instant results helping businesses, governments and individuals to
protect themselves and those around them from the ravages of disease and
addiction. CCR will be a major
contributor to the physical and economic health of the world.
Market
Trend
We
believe the market trend is to deliver faster, cheaper and more reliable
testing for disease and also use this capability to help manage the most common
addictions. These complimentary services
will improve business performance, reduce the burden on governments and improve
the health of the global humanity. CCR
is placing itself to be at the beginning of this revolution in health care and
available to all to use.
Competitors
Abbott is the dominant player in Covid Diagnostics. In 2021, its revenue was $34.61bn. It is an early player, receiving its
emergency authorization from the US Food and Drug Administration in March 2021
for its expanding Covid diagnostic product line. CCR will target Abbott as it source of market
share going forward. Other major
competitors in the US include, Danaher and The Quidel Corporation.
Sales
and Marketing
Strategy
CCR
will base its marketing on it USP’s of price and place. Specifically, a low-cost service with sample
collecting and, if required, testing occurring in or near the location of the
customer. The product is the end-to-end
service and will be priced accordingly.
The accuracy of the test will be equivalent to the competitors, but it
is the service delivery and price that are the central pillars to the sales and
marketing strategy.
In
short, our strategy will be to penetrate the market with a national advertising
campaign and take market share via targeted incentives and mature the business
via high test accuracy and reliable delivery.
Method
of Sales
Covid
19 management will be the headline in the CCR marketing strategy. Covid 19 is still very much a threat to
humanity, and we believe the CCR Covid testing service will bring awareness to
customers of our other offerings. CCR
will employ the following advertising methods and mediums to find our
customers:
a.
CCR will push our services via the
Internet portal and email shots – Direct Marketing.
b.
Awareness Campaign with our retail partner
CVS. Instore posters, product
information flyers (point of sale collateral) and training of CVS staff.
c.
Awareness campaign via TV and Radio.
d.
Awareness campaign via National
Newspapers.
e.
Awareness campaign to doctors and
hospitals across the USA.
f.
Testimonials via YouTube and other social
media platforms.
g.
In Person representation/demonstration to
our b2b customers.
Online
Advertising
This
offers the best bang for the buck return on the marketing budget. Given those who are sick are likely to be
self-isolating anyway this is the most logical place to make are biggest
investment from the Marketing budget.
CCR will employ specialist online marketing agencies to ensure search
engines propel the CCR message at the top of the Google Search engine results
for 6 top search words and phrases regarding Covid and disease testing. CCR’s competitive advantage will not only be
the first message our potential customers will be exposed to, but our price,
turnaround speeds and national; coverage will demand sales from the potential
customer base over our competitors.
The
ease of our online sales portal will also mean the think time from
consideration to payment will be as short as possible. CCR already has agreement with PayPal, Visa,
Mastercard, Google Pay, Samsung Pay and others to offer their 2 click payment
service. This, and a simple path from
“interest to payment” website, will increase CCR’s ability to convert more
views into sales than any of our competitors.
Newspaper
and Online Testimonials Advertising
These
will be used to establish interest and trust in the CCR brand. Accuracy comparators, YouTube “How To’s”,
real life experiences will all be used to create talk triggers with potential
customer communities. We intend these to
be multicultural in nature and try to lever in communities that have been to
date sceptical of Covid testing and distrustful of this industry
generally. CCR is an ethical company
with wellbeing of humanity as important as profit.
In
Person Promotion and Demonstration (B2B Customers)
The
competitive edge CCR has over its competitors is the short lead time of its Premium
Service. We aggressively promote this
USP to business and government customers.
Given the Covid epidemic is still a major risk for these potential
customers CCR will use this leverage to demonstrate the speed, convenience, and
accuracy of the Premium Service to B2B customers in real time. We will take a mobile testing unit to site
and return buyers an accurate test within 2 hours of the sample taken.
B2B
Bundles
CCR
will offer bundle packages to corporate and government customers. This is seen as a way to fund, develop and
pilot the commercial testing of other diseases and addiction management that
will form the core of the CCR initial product range. The
bundles will be a bespoke blend of combined Covid testing and addiction testing
and counselling services. This will be a
POA Service bundle that will share economies of scale and the single-entry
point to CCR’s testing facility cost efficiencies with the corporate customer. At all times this will depend on the customer
need and therefore bespoke and appropriate.
All these services will be available to the customer within the first
year of trading to complete the product mix.
Estimated
Sales Potential USA
|
Year |
2023 |
2024 |
2025 |
2026 |
|
Sales C-19 (Mn) |
100 |
200 |
300 |
500 |
|
Turnover
($Mn) |
587.5 |
1175 |
1748.6 |
2941.5 |
Our sales predictions are given below,
and the figures anticipate 70-30 Split between the Standard and Premium
Services and a 50-50 split between antibody and gnome.
Table 4: Estimated Sales
The
going rate for a Covid 19 test at CVS is $99.
This is a typical price for a Covid Test and shows the strength of the
CCR pricing proposal. By using the
low-price entry point into the market CCR will seize market share before the
market has time to react and use its advantage to drive better deals with our
suppliers to keep costs below that of our competitors. CCR pricing strategy is about high volume-low
costs, dominant market share and position.
Promotion
Plan for Market Penetration
To penetrate the market
CCR the following incentives will be employed:
a.
5000 Free tests will be offered to B2C
customers in the first 3 months of trading via our web portal. These will be of the standard service and a
loss leader designed to drive talk triggers in the market.
b.
For the first 3 months of trading B2C
customers of the premium service will receive a 30% discount. This will mean we deliver this incentive at
cost.
c.
Doctors and hospitals offering our
services will receive a 30% discount of all our services to their employees for
the first year of trading. This will
mean we deliver this incentive at cost.
d.
B2B customers (government and large
businesses over 500 employees) will receive a 30% discount in the first trading
year. This will mean we will deliver
this service at cost.
4
“P’s” Summary:
Product:
The Disease Testing and Addiction Management Services:
a.
B2C Two speed Covid Testing
a.
Premium Service: Results within 2 hours,
test comes to customer.
b.
Standard Service: Results within 48hrs,
sample mailed to CCR.
b.
B2C Other Disease Testing – Premium and
Standard Service offerings with timelines dictated by disease. Service definition to be confirmed.
c.
B2C Addiction Management – Testing for intoxicants
and counselling combined in an ongoing service offering.
d.
B2B – The above services offered in
bundles depending on the customer requirement.
P
Price: The retail cost of the CCR services.
CCR
will significantly undercut our competitors by at least 50%.
Promotion: The Method CCR will raise awareness of the
product mix:
Online,
print, in-person and retail.
Place: The location where CCR services will be
marketed.
Online
Portal, Retail (CVS initially), Doctors Surgeries, Hospitals, Workplace, Homes.
Distribution
Channels
Direct: CCR to the customer directly.
- Standard
Service Test Kit, CCR to customer via web portal online ordering.
- Premium
Service, CCR to customer via web portal and mobile home testing team.
- Addiction
Services, CCR to customer via web portal and bundled testing and
counselling.
Retail: CCR to the customer via a retail outlet such
as CVS and a doctors surgery or hospital.
a. CCR to CVS (retailer) to customer.
b. CCR to Doctors/Hospitals to customer.
Ongoing
Growth Ambition
Overall,
the Marketing and Sales strategy for CCR is a balanced and achievable
proposition that will ensure good lift into the market and ensure ongoing
growth through years 1 through 3. There
after growth will be achieved in two ways:
1. Expanding
Services: As CCR’s
expertise and market foothold expands investment into new services will include
other diseases and addictions. This
includes gambling and self-mutilation addictions and diseases that may not be
prevalent in the US but are common in other parts of the world. These include Malaria, Plague, Tsetse Fly
(Sleeping Sickness), and Leprosy.
2. Expanding
Global Footprint: With
the rapid growth predicted in the US, CCR will, invest in expanding from the
USA into the wider North America and beyond.
This may be by franchise but at the moment CCR is minded to becoming a
multinational. Operating across
countries, with discrete research and revenue streams seems to be the best way
to offset any adverse global market forces and increase the company’s knowledge
base of disease and addiction management.
In Short, CCR is setting a path to be a global player in this market
from the outset. We will learn and
develop our product mix and supply chains into a broad, profitable and
resilient global business delivering humanity changing solutions to 21st
Century health problems.
Slogan
“First
in Global Disease and Addiction Testing and Management”
Character/Spokesman
All members of the CCR
top management are able communicators but the CEO, Steve Rattley, will
represent the company for the purposes of investment.
Management and Ownership
CCR
will have the following Senior Management Structure:
CCR
is an incorporated business and as such complies with the required state and
federal legislation of the United States of America. Steve Rattley in the first CEO of CCR, as
such he is responsible for corporate strategy.
He is the spokesperson for the company using his strong interpersonal and
global management skills. He is an
experienced entrepreneur with a successful track record of lifting new
businesses and delivering best practise governance. Steve presently owns a 25% holding in CCR.
The
Chief Operating Officer is Cam Babula.
He graduated from Mercer County Community College with an overall GPA of
4. Mentored by his father, he then went
on to own a selection of gardening businesses across New Jersey before
graduating from Harvard specialising in process engineering. Using his strong inter-relationship and
conceptual skills Cam will also oversee the company’s HR Management. Cam presently owns a 25% holding in CCR.
Connor
McHale, a former decorated policeman and restaurateur, brings rigor and
integrity to the financial operations of CCR.
Another gifted member of the Mercer alumni, Connor met Steve Rattley
whilst studying there. Before becoming a
member of the Chartered Institute of Management Accountants, Connor with Steve
were the powerhouse behind the “Rest and Test” franchise of simple and cheap to
eat hostelries with a Covid testing booth on premises seen in most cities
across the US. That project is CCR. Connor presently holds a 25% holding in CCR.
The
final member of the CCR management team is Dr A Lynch, Chief Scientific
Officer. Mentor to Steve, Connor and Cam
at Mercer County Community College, Dr Lynch is an experienced businesswoman,
academic and guardian of clinical compliance and excellence within CCR. As the clinical lead she works closely with
Cam Babula, COO, in the recruitment of senior clinical staff. She completes the formidable senior team. Dr Lynch presently holds a 25% holding in
CCR. All the above top managers comprise
the CCR Management Board and presently, develop and execute the Corporate,
Business and Functional strategies of CCR.
They also deliver with their senior managers CCR’s Crisis, Tactical and
Operational Plans.
Legal
and Regulatory Responsibilities
The
health industry demands conformance with national and international hygiene,
process and handling standards and regulations.
These concerns are mitigated by buying kits off the shelf (from Roche
say). This limits CCR’s liability to
process and handling rather than efficacy and kit design. CCR seeks to employ from the considerable
health and laboratory conditioned labor force centred in Philadelphia. Our labs will be certified in accordance with
the required regulations and this duty will be delegated by the board to
Directors and managers of the business.
All
sample and collection handling will be performed by trained operators
conforming to the appropriate ISO and legal standards necessary under control
of the CCR CSO, Dr Lynch.
Financials
Risks
The
top three risks are the following:
a.
Suppliers Fail to Deliver Testing
Components: Impact: High, Likelihood: Medium/High. This risk will be treated. CCR has identified several other suppliers of
testing components. Whilst no firm
orders are foreseen at this time alternate suppliers have been identified and
are aware of the CCR launch via a Non-Disclosure Agreement and have given
anecdotal assurance stock is available throughout the year due to high
production levels and a globally prioritised and protected supply chain.
b.
Competitors Engage in a Pricing War: Impact: Medium, Likelihood Medium. This risk will be tolerated in the first
year. It is mitigated by the heavy
discounts used to penetrate the market.
CCR believes these discounts will make the likelihood of our competitors
stalling the CCR lift unlikely. The hit
on profits would be important however as our financial forecasting will fall to
its worst-case scenario. 5% of profit in
the first trading year will be retained in the event this risk becomes an issue
by way of mitigation.
c.
Sales Estimates Are Not Achieved: Impact: Medium, Likelihood: Low. This risk will be tolerated. Market research and the emergence of new
strains of Covid suggest demand for CCR services is only likely to increase
especially considering the low pricing point and convenience of the services
offered.
d.
Legal and Regulatory.
Impact: Medium, Likelihood Low. The risk
will be tolerated, mitigated by the well-developed extant Covid
technology/method and compliance with national and international best practises
and legal conformance and inspection. In
addition, CCR will transfer this risk from its corporate risk register into Dr
Lynch’s (CCR Chief Scientific Officer) terms of reference. This is the key element of her ongoing role
for the company. The health industry
demands conformance with national and international hygiene, process and
handling standards and regulations.
These concerns are mitigated by buying kits off the shelf (from Roche
say). This limits CCR’s liability to
process and handling rather than efficacy and kit design. CCR seeks to employ from the considerable
health and laboratory conditioned labor force centred in Philadelphia. Our labs will be certified in accordance with
the required regulations and this duty will be delegated by the board to
Directors and managers of the business.
All sample and collection handling will be performed by trained
operators conforming to the appropriate ISO and legal standards necessary.
Covid
Testing (Premium and Standard Service) Profit Margin
Table 5: Product Cost/Retail Price
Premium Service
|
|
Total
Cost ($) |
Retail Per Test ($) |
|
C19
- Antibody |
0.73 |
1.10 |
|
C19
- Gnome |
7.1 |
10.65 |
Product
Cost/Retail Price Standard Service (Table 6)
|
|
Total
Cost ($) |
Retail Per Test ($) |
|
C19
- Antibody |
0.73 |
0.95 |
|
C19
- Gnome |
7.1 |
9.14 |
Balance
Sheet – April 2022 (Table 7)
|
CCR Balance Sheet 2022 |
|||
|
Asset |
Value $ |
Liability |
Value $ |
|
Cash |
$ 485,000 |
Rent |
$ - |
|
Supplies |
$ 567,000 |
Borrowings |
$ - |
|
Inventory |
$ 623,000 |
Pre-paid Customers |
$ 400,000 |
|
Pre Paid Rent |
$ 100,000 |
Equipment Rent |
$ 12,000 |
|
Pre-Paids |
$ - |
|
|
|
Building |
$ - |
Total |
$ 412,000 |
|
Motor Vehicles |
$ 120,000 |
|
|
|
Lab Equipment |
$ 367,000 |
Shareholder Equity |
$ 1,850,000 |
|
|
|
|
|
|
Total: |
$ 2,262,000 |
Total: |
$ 2,262,000 |
Income Statement (Profit
and Loss) - April 2022 (Table 8)
|
Income
Statement (Profit/Loss) - April 2022 |
|
|
Revenue |
Value $ |
|
Total Sales |
$ 10,189,082 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
$ 10,189,082 |
|
|
|
|
Expenses |
Value $ |
|
Pay |
$ 780,000 |
|
Advertising/Marketing/Web |
$ 163,000 |
|
Vehicle Servicing/Repair/Gas |
$ 123,000 |
|
Testing Kits (Gnome) |
$ 7,100,000 |
|
Testing Kits (Anti) |
$ 87,600 |
|
Testing Kits (Other) |
$ 12,000 |
|
Testing/Addiction Svc Costs |
$ 22,000.00 |
|
|
|
|
Total |
$ 8,287,600 |
|
|
|
|
Total Profit: |
$ 1,901,482 |
Sales – April 2022
|
April
Sales |
|||
|
Service |
Quantity |
Unit Value $ |
Total |
|
Covid Standard (Anti) |
34123 |
$ 9.14 |
$ 311,884.22 |
|
Covid Standard (Gnome) |
2345 |
$ 0.95 |
$ 2,227.75 |
|
Covid Premium (Anti) |
86675 |
$ 1.10 |
$ 95,342.50 |
|
Covid Premium (Gnome) |
900012 |
$ 10.65 |
$ 9,585,127.80 |
|
Other Tests |
2100 |
$ 5.00 |
$ 10,500.00 |
|
Addiction Management |
460 |
$ 400.00 |
$ 184,000.00 |
|
Total Sale Revenue |
|
|
$ 10,189,082.27 |
Testing Kit Cost – April
2022
|
April
Testing Kit Costs |
|||
|
Service |
Quantity |
Unit Value $ |
Total $ |
|
Covid (Anti) |
120000 |
$ 0.73 |
$ 87,600.00 |
|
Covid (Gnome) |
1000000 |
$ 7.10 |
$ 7,100,000.00 |
|
Other Tests |
3000 |
$ 4.00 |
$ 12,000.00 |
|
Total: |
|
|
$ 7,199,600.00 |
Capital Requirement
This
business case seeks to solicit $2.5bn in start-up capital to roll out CCR
across the US, strengthen its supply chain and increase its expenditure on
product development and marketing. This investment
will secure a 49% share of the company.
The return on investment is projected to be $324m (EBIT) in the first
year of trading nationally. With the
expansion plans outlined it is expected that this return on investment will
grow strongly as CCR spreads its service across the country and then the globe. This is a growing industry with true global
potential. You are invited to be in at
the start of this revolution in health care that will fertilise your bottom
line and become a major force in doing good across the world.
No comments:
Post a Comment